An Open-Label Study to Determine the Pharmacokinetics of a Single Dose of DZNS in Adult Epileptic Patients Experiencing a Seizure Episode for Which Acute Treatment With a Benzodiazepine is Clinically Indicated.

Trial Profile

An Open-Label Study to Determine the Pharmacokinetics of a Single Dose of DZNS in Adult Epileptic Patients Experiencing a Seizure Episode for Which Acute Treatment With a Benzodiazepine is Clinically Indicated.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Diazepam (Primary)
  • Indications Seizures
  • Focus Pharmacokinetics
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 25 Jun 2013 Results presented at the International Congress of the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE), according to an Acorda Therapeutics media release.
    • 03 Apr 2013 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top